ARAF and cancer: Drug repurposing has been the most promising strategy in many studies focused on using Schistosoma PKs as molecular targets, and the success of using this class of inhibitors to treat cancer and chronic diseases might translate to the development of novel alternatives to treat parasitic diseases.